Search results for " metastasis"
showing 10 items of 623 documents
An Open-Label Phase II Study Evaluating the Safety and Efficacy of Ramucirumab Combined With mFOLFOX-6 as First-Line Therapy for Metastatic Colorecta…
2014
Abstract Author Summary Background. Vascular endothelial growth factor (VEGF) and VEGF receptor 2 (VEGFR-2) are believed to mediate angiogenesis in colorectal cancer (CRC). Ramucirumab (RAM; IMC-1121B) is a human IgG1 monoclonal antibody that inhibits VEGF ligand binding to VEGFR-2, inhibiting VEGFR-2 activation and signaling. Methods. Patients with metastatic CRC, Eastern Cooperative Oncology Group performance status 0–1, and adequate organ function who had not received chemotherapy for metastatic disease received RAM and the modified FOLFOX-6 regimen every 2 weeks. Endpoints included progression-free survival (PFS), objective response rate, overall survival, and safety. The sample size wa…
The waiting time for prostate cancer treatment in Italy: analysis from the PROS-IT CNR Study.
2022
Background Prostate cancer (PCa) is the second most common neoplasm in male patients. To date, there's no certain indication about the maximum waiting time (WT) acceptable for treatment beginning and the impact on oncological and functional outcomes has not been well established. Methods Data from the National Research Council PCa monitoring multicenter project in Italy (Pros-IT CNR) were prospectively collected and analyzed. WT was defined as the time from the bioptical diagnosis of PCa to the first treatment received. Patients were divided in two groups, using a time frame of 90 days. Quality of life was measured through the Italian version of the University of California Los Angeles-Pros…
Adipose stem cells on the basis of tumor transformation
Mesenchymal stem cells thanks to their differentiated multipotent ability are considered the most promising candidate for tissue engineering and regenerative medicine. The source of mesenchymal stem cells up to about 20 years was represented by the bone marrow, but due to their limited amount of cells together with a very invasive and painfull surgical treatment, poorly accepted by patients, has led the scientific community to investigate an alternative mesenchymal stem cells source with similar properties. In particular, the adipose tissue has attracted the greatest interest thanks to its relative abundance, the easy of availability and the large amounts of mesenchymal stem cells which are…
EFFICACY OF ZOLEDRONIC ACID IN PATIENTS WITH COLORECTAL CANCER METASTATIC TO BONE
2010
Introduction. Bone metastases are an emerging clinical problem in colorectal cancer patients probably related to survival increase. There are no data in literature about the role of BPs in the treatment of bone disease from colorectal cancer. We present the final data of a large Italian multicenter retrospective analysis. Methods. 264 colorectal cancer patients with occurrence of bone metastases have been included in the study. All patients were dead due to cancer at the moment of the study inclusion. Patients characteristics, Skeletal Related Events (SRE) data and median survival after bone metastases appearance have been collected in a master data base and statistically analyzed. The prim…
Nab-paclitaxel in pretreated metastatic breast cancer: evaluation of activity, safety, and quality of life
2019
Rossella De Luca,1 Giuseppe Profita,2 Giuseppe Cicero1 1Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy; 2Department of Surgical, Oncological and Oral Sciences, Section of Surgical, University of Palermo, Palermo, Italy Objective: Metastatic breast cancer (MBC) is an incurable disease; the treatment of this disease prolongs survival, improving the quality of life (QoL) with a balance between efficacy and toxicity of the treatment. In recent years, treatment with nab-paclitaxel has improved the already known antitumor activity of conventional paclitaxel, in terms of increased efficacy and better tolerability. The aim o…
Cancer Stem Cells: From Birth to Death
2019
Abstract Conspicuous investigations have proven the role of cancer stem cells (CSCs) in the onset and progression of a plethora of liquid and solid neoplasms. CSCs are endowed with the capability of initiating tumor growth and becoming dormant at distant organ sites just waiting for optimal conditions amenable for metastatic outgrowth. This cancer subpopulation is inherently resistant to anticancer therapeutics, and its targeting could avoid metastatic disease, which is largely incurable, and clinical relapses. CSCs are considered the Achilles heel of cancer. However, many efforts are necessary to identify univocal CSC markers as well as specific CSC biomarkers of therapeutic response. Here…
TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells
2015
Metastatic growth in breast cancer (BC) has been proposed as an exclusive property of cancer stem cells (CSCs). However, formal proof of their identity as cells of origin of recurrences at distant sites and the molecular events that may contribute to tumor cell dissemination and metastasis development are yet to be elucidated. In this study, we analyzed a set of patient-derived breast cancer stem cell (BCSC) lines. We found that in vitro BCSCs exhibit a higher chemoresistance and migratory potential when compared with differentiated, nontumorigenic, breast cancer cells (dBCCs). By developing an in vivo metastatic model simulating the disease of patients with early BC, we observed that BCSCs…
Cathepsin L in Normal and Pathological Bone Remodeling
2011
Abstract Cathepsin L is a ubiquitous lysosomal cysteine endopeptidase that is mainly involved in the metabolic turnover of intracellular proteins. However, it is now well established that this enzyme may also be implicated in the regulation of other important biological processes includ- ing bone resorption. Therefore, altered expression levels of Cathepsin L may result in disturbances of bone homeo- stasis and, eventually, in the onset of pathological condi- tions associated with altered bone turnover. These observations support the concept that Cathepsin L may be regarded as an additional target for the development of novel therapeutic options for the treatment of patients with bone disea…
Endurance training induces apoptosis in the tumor mass in the C26-bearing mouse model
2018
A CRF-Producing and -Secreting Tumor of the Lung
1986
Corticotropin-releasing factor (CRF) has recently been isolated from ovine hypothalamus, characterized chemically, and synthesized. Upton and Amatruda (1971) first suggested that CRF-like activity occurred in neoplastic tissues, and Hashimoto et al. (1980) subsequently detected CRF-like activity in an extract of an ACTHproducing nephroblastoma. Recently, Carey et al. (1984) and Asa et al. (1984) used immunocytochemical techniques to demonstrate CRF in postmortem tumor material obtained from patients with a carcinoma of the prostate and an intrasellar gangliocytoma.